Abstract
Enzyme immobilization is an important strategy to enhance the stability and recoverability of enzymes and to facilitate the separation of enzymes from reaction products. However, enzyme purification followed by separate chemical steps to allow immobilization on a solid support reduces the efficiency and yield of the active enzyme. Here we describe polypeptide constructs that self-assemble spontaneously into nanofibrils with fused active enzyme subunits displayed on the amyloid fibril surface. We measured the steady-state kinetic parameters for the appended enzymes in situ within fibrils and compare these with the identical protein constructs in solution. Finally, we demonstrated that the fibrils can be recycled and reused in functional assays both in conventional batch processes and in a continuous-flow microreactor.
Keywords: enzyme catalysis, immobilization, kinetics, microreactors, nanostructures
Introduction
Amyloid fibrils are stable, highly ordered polypeptide aggregates, the assembly of which can be controlled in vitro by altering conditions such as temperature, degree of agitation, and the presence of cosolvents. Several diseases are associated with the accumulation of amyloid fibrils,1 yet examples of amyloid fibrils that occur naturally with positive biological functions have also been identified recently, which include the curli proteins of Escherichia coli and Ure2 of Saccharomyces cerevisiae.2 Fibril morphology and structure are affected by the assembly conditions and the presence, position, and conformation of molecules appended to the amyloidogenic domain.3 The extraordinary stability and tunable assembly of amyloid fibrils make them attractive targets as nanomaterials;4 indeed, the functionalization of amyloid fibrils by metal binding and cytochrome display has already been explored5 and significant signal enhancements have been demonstrated if amyloid fibrils are employed in immuno- or biosensor assays.6
Ure2 is a regulator of nitrogen metabolism in S. cerevisiae through its conformation-dependent interactions with the transcription factor Gln3. The fibrillar form of Ure2 propagates in a manner analogous to mammalian prions,2b which makes it a useful tool to enhance the understanding of prions in general. Although no high-resolution structural data have yet been obtained, several recent structural studies on Ure2 fibrils have proposed the following model: the N-terminal prion domain (residues 1–93), which is rich in Asn and Gln residues and is necessary and sufficient for fibril formation in vitro and prion propagation in vivo7 forms a cross-β fibril core, around which the C-terminal globular domains are displayed.8 The C-terminal domain (CTD), a structural homologue of glutathione transferase enzymes,9 forms a homodimer and shows glutathione peroxidase and glutaredoxin activities in both the soluble and fibrillar forms of the protein.10
The central core of the Ure2 fibril is formed from the first 80 residues.8b Residues 81–100 provide flexibility between the prion domain and the CTD; this is important for the amyloid formation of Ure211 and also offers the possibility of replacing the CTD with other proteins.8a Although the appendage of globular proteins to some amyloidogenic peptides requires that the globular protein first unfolds for fibrils to form,12 the globular C domain of Ure2 is accommodated in its native state within the fibrils.8a, 10
The value and use of commercial and industrial enzymes can be enhanced by immobilization. A key advantage of this process is the introduction of a phase separation between the enzyme and the reaction mixture, which facilitates the recovery and reuse of the enzyme and purification of the product. Immobilization has relied traditionally on four strategies: adsorption, covalent attachment of enzymes to carriers, entrapment, and chemical cross-linking.13 However, each of these methods may reduce the proportion of conformationally active enzyme, reduce flexibility, or limit the access of the substrate to the enzyme. Although some nanostructures, such as nanoparticles, nanofibers, and mesoporous silica, have been tested as immobilization materials to improve the surface-area-to-volume ratio, limitations in terms of dispersion in solution, a substrate diffusion barrier, efficiency of enzyme immobilization, and ability to recycle still remain.14 Thus, there is a significant driving force for the development of alternative methods for enzyme immobilization.
Several recent studies indicate a strong interest in the possibility of using amyloid fibrils as a scaffold for the immobilization of proteins of biological or chemical interest.3b, 4–6 Chemical cross-linking has been used to attach an enzyme to an amyloid scaffold.4b However, the cross-linking approach is inevitably hard to control and leads to heterogeneity of the system and potential modification of the molecule of interest. In contrast, the genetic fusion approach applied here leads to highly efficient and homogenous self-assembly. Previous studies have used the prion domain of another yeast prion protein, Sup35, as the fibril-forming component of a fusion protein nanowire that comprises monomeric proteins that fold reliably when overexpressed.6 Likewise, an earlier study indicated the potential of the Ure2 prion domain to form fibrils containing appended enzymes, at least for proteins that are expressed and folded easily.8a In contrast, we have explored the possibility of using the Ure2 prion domain to display enzymes with specific folding requirements and diverse architectures and we have chosen alkaline phosphatase (AP) and horseradish peroxidase (HRP) as industrially important enzyme models. We exploit the homogeneity of the system to perform quantitative characterization of enzymatic parameters for both soluble and fibrillar forms of the genetically fused constructs. Finally, we demonstrate the practical application of the enzymatically active fibrils to immobilize and, thereby, recycle and reuse the enzymes in both traditional batch processes and as the basis for flow chemistry in microfluidic channels.
Results and Discussion
Chimeric AP and HRP form fibrils with the cross-β architecture characteristic of amyloid
The prion domain of Ure2 was attached to the N terminus of AP or HRP, both of which have widespread applications in clinical and immunodiagnostic use and can be assessed for activity using simple colorimetric, fluorescent, or luminescent assays even at low (single molecule) concentrations, which raises the possibility of using our chimeras to probe the assembly and subunit structure of Ure2. AP assembles as a mirror symmetric dimer (unlike the wild-type (WT) Ure2 dimer, which has axial symmetry) and catalyzes the hydrolysis of mono- and diphosphoesters from a range of substrates. HRP is a monomeric hemoglycoprotein enzyme capable of the very rapid turnover of a range of synthetic substrates. It forms inclusion bodies if overexpressed in E. coli and requires refolding in vitro (which includes the formation of four disulfide bonds and the incorporation of one heme cofactor and two Ca2+ ions) to achieve its active conformation15 (see Supporting Information).
All the chimeric proteins formed fibrillar aggregates, which were characterized by negative-staining TEM, circular dichroism (CD) spectroscopy, and X-ray fiber diffraction (Figure 1). The fibril morphologies were similar to that of WT Ure2 and their widths were consistent with the relative monomeric molecular weights of the soluble proteins (WT Ure2 CTD, 29.8 kDa; AP, 49.4 kDa; HRP, 34.0 kDa). CD spectroscopy revealed a significant increase in the proportion of β-sheet secondary structure after fibril formation, consistent with the assembly of proteins into cross-β amyloid fibrils (Figure 1 B and C), and X-ray fiber diffraction of dry stalks gave rise to anisotropic reflections at 4.7 and 10 Å for Ure21−93-AP and Ure21−80-HRP fibrils, respectively, characteristic of the presence of a cross-β fibril core16 (Figure 1 D and E) similar to that of WT Ure2.8d, 17
AP and HRP chimeric fibrils show enzymatic activity: Insight into the effects of enzyme immobilization from steady-state kinetic parameters
Similar to WT Ure2,10 our chimeras retained their enzyme activities after fibril formation. Activities were measured for both soluble and fibrillar samples at a range of substrate concentrations, and the steady-state enzyme kinetics data for the chimeras were compared to those of WT AP and WT HRP. The substrates used were p-nitrophenyl phosphate (pNPP) and 2,2′-azinobis-(3-ethylbenzthioazoline-6-sulfonic acid) diammonium salt (ABTS) for AP and HRP, respectively. The kinetic parameters obtained are shown in Table 1. Attachment of the Ure2 prion domain to the N terminus of AP appeared to lower the affinity of the enzyme for the substrate after the formation of amyloid fibrils, as suggested by an increase in the apparent Michaelis constant (KM), whereas the soluble chimera showed a more similar KM value to that of WT AP. Soluble and fibrillar forms of Ure21−93-AP showed similar catalytic activities, around 10-fold lower than that of WT AP, as indicated by the turnover number at saturation, kcat. This suggests that the observed reduction in catalytic activity is a result of the addition of the fusion itself, which may partially compromise the folded structure of AP. However, within the fibrils, the native AP molecules are displayed in a manner that is readily accessible to the substrate and catalyzes the phosphatase reaction with similar efficiency to the soluble form of the same enzyme construct.
Table 1.
Enzyme | Construct | kcat [s−1][a] | KM [μm][a] | kcat/KM [μm−1 s−1][a] |
---|---|---|---|---|
AP | WT AP | 45.3±1.4 | 23±1 | 1.97 |
Ure21−93-AP | 3.3±0.1 | 35±5 | 0.09 | |
Ure21−93-AP (fibril) | 4.0±0.3 | 94±24 | 0.04 | |
HRP | WT HRP | 592±18 | 412±22 | 1.44 |
Ure21−80-HRP | 219±13 | 258±25 | 0.85 | |
Ure21−93-HRP | 155±17 | 197±39 | 0.79 | |
Ure21−80-HRP (fibril) | 72±3 | 604±51 | 0.12 | |
Ure21−93-HRP (fibril) | 31±2 | 410±36 | 0.08 |
[a] The errors shown are the standard error of the fit of the data shown in Figure S3 in the Supporting Information.
The full-length prion domain (residues 1–93) was fused to the N terminus of HRP, but the activity of the resulting fibrils was low. The shortening of the prion domain (using only residues 1–80, which has previously been shown to allow fibril formation of the prion domain8b) led to an approximate doubling of the catalytic activity for the fibrillar form. As a result of the nature of the peroxidase reaction cycle (a ping pong mechanism dominated by compulsory second-order steps18), the apparent KM cannot be equated directly with substrate affinity. The ratio of kcat/KM is, however, a relative estimate of the slowest second-order step k3 (the rate for substrate association, which corresponds to the reduction of compound II to resting enzyme19) in the catalytic cycle.18 This parameter shows a dramatic decrease for the fibrillar form compared with the soluble form. The most probable explanation for this is reduced enzyme activity because of the steric hindrance of substrate access to the aromatic donor binding site at the reactive heme edge (centered on Phe 179 in WT HRP18). The more marked effect on catalytic activity upon fibril formation for HRP compared to AP is consistent with the very high turnover number of HRP, which means that the rate of catalysis is essentially diffusion controlled.
Chimeric fibrils of AP and HRP display a similar fibril core structure to WT Ure2
The fibril core can be identified by its resistance to proteases. We used proteinase K digestion and Western blotting to assess the composition of the fibril cores of our chimeric protein fibrils. All fibrils were treated for at least 24 h with 0.5 mg mL−1 proteinase K, a broad-spectrum serine protease that cleaves next to aliphatic and aromatic residues, and the fibril cores that remained were analyzed by TEM. Similar core widths (6–8 nm) were observed for all samples (Figure 2 A), and washed pellets that contained only the fibril cores did not show any enzymatic activity against the test substrates.
The composition of the fibril cores was also tested by Western blot using an anti-Ure2 primary antibody. After proteinase K digestion, the fibril cores were washed with buffer and dissolved in 8 m urea with 2 % sodium dodecyl sulfate (SDS) for polyacrylamide gel electrophoresis (PAGE). Protein bands that correspond to the fibril cores do not stain efficiently with Coomassie Blue, but silver staining revealed smeared bands around 13 kDa in size, which correspond to the dissolved fibril core. These bands showed immunospecificity to the anti-Ure2 antibody, whereas degraded WT AP and HRP (negative controls) were not recognized by the antibody (Figure 2 B).
Further evidence that the chimeric proteins share the same fibril core as WT Ure2 comes from cross-seeding assays. The fibril formation of Ure2 and Ure21−93-AP was seeded with WT Ure2 and chimeric protein fibril seeds and monitored by thioflavin T (ThT) fluorescence. A decrease in the lag phase of WT Ure2 and Ure21−93-AP fibril formation was observed after seeding (Figure 3 A and B).
The self-assembly of Ure21−93-HRP and Ure21−80-HRP was monitored by TEM because fibril formation did not give rise to any change in ThT fluorescence, perhaps because of quenching by HRP-bound heme. Large fibrils were observed after seeding, whereas no fibrils were observed in the nonseeded samples (Figure S1 A and B in the Supporting Information). All fibril seeds appeared as short rods in the TEM images, and no change was observed after 3 h incubation under the conditions of the seeding assay in the absence of soluble protein (Figure S1 C in the Supporting Information). WT Ure2 and Ure2 chimeras were able to cross-seed each other’s growth, which suggests that the stacking within these fibrils (i.e., the structure of the fibril core) is similar. This is consistent with a model in which the fibril cores are formed of the prion domain of Ure2, and AP/HRP is displayed on the surface, which has been suggested previously for fibrils of WT Ure2.8
Chimeric fibrils can be recycled in functional assays in both batch processes and in a continuous-flow microreactor
One of the primary goals of enzyme immobilization is the ability to recover and reuse enzymes. This is significant economically but also facilitates subsequent purification of the product by the full removal of one component of the reaction mixture in bulk. Our chimeric fibrils could, for instance, be reacted with substrate repeatedly, recovered by centrifugation, washed, and then recycled with minimal loss of yield or activity after each round of reaction and recycling (Figure S2 in the Supporting Information).
In addition to enzyme recovery through batch processes such as centrifugation, the availability of the enzymatically functionalized nanoscaffold architecture developed in this study also opens up the possibility of using flow chemistry to perform reactions under continuous-flow conditions in which the separation of the active enzymes from the reaction products occurs in a continuous manner. We demonstrated this idea by packing chimeric fibrils into a microcolumn and found that the substrate could be readily pumped in and the product could be collected in the flow-through (Figure 4). The fibrils could be washed repeatedly and reused with the same or different substrates. No cross-reactivity between substrates was found after washing with buffer. This finding confirms that the fibrils are stable in dilute solution and can be efficiently recycled and reused. Furthermore, they can be readily applied in microscale detection and high-throughput measurements.
To further confirm whether the level of activity retained in our fibril-immobilized enzymes has any potential commercial or industrial application, we tested the possibility of using Ure21−93-AP fibrils in place of shrimp alkaline phosphatase (SAP). SAP is used routinely in molecular biology to remove 5′ phosphate groups from DNA to prevent self-ligation. After reaction, it is necessary to remove or inactivate the SAP so that the target DNA insert is not also dephosphorylated. This is normally achieved by irreversible heat inactivation of the enzyme by incubation at 70 °C for 30 min. To test whether Ure21−93-AP fibrils are as effective as SAP at dephosphorylating DNA, a blue/white selection assay was used. Top10 E. coli were transformed with DNA that had been treated with buffer, SAP, or Ure21−93-AP fibrils before ligation, and the proportion of blue/white colonies was determined. Blue colonies indicate the religation of the vector without gene insertion, whereas white colonies indicate successful gene insertion.
The immobilized AP was recycled and re-reacted with the same linear plasmid (pUC19) to test its recyclability. Meanwhile, another plasmid (pHSG299) with different antibiotic resistance was used to check for plasmid contamination from the previous reaction when Ure21−93-AP fibrils are reused. The results of the screening assay are shown in Figure 5. Not only do Ure21−93-AP fibrils catalyze the phosphatase reaction as efficiently as commercial SAP but they can also be recovered and recycled with the same proportion of positive colonies and without plasmid contamination from previous reactions. Furthermore, the ability to separate Ure21−93-AP fibrils easily from the reaction mixture, and the lack of requirement for heat denaturation, means that immobilized AP is more convenient to use than SAP. Thus, Ure21−93-AP fibrils offer a sustainable and cost-effective alternative to the use of SAP in molecular biology.
Conclusions
In our system, the prion domain of Ure2 provides a naturally stable linker between the fibril core and enzymatic domain and allows the immobilization of the enzymes with high efficiency and homogeneity. The tunable self-assembly of our system, the ability to separate enzymes from substrate/product by centrifugation or trapping within a column, and the excellent recyclability of our enzymatic fibrils satisfy the requirements for efficient enzyme immobilization. The enzymes we have chosen to append to the Ure2 prion domain demonstrate the capacity of this domain to support a variety of molecular sizes and architectures. Alkaline phosphatase is nearly twice the size of the Ure2 C-terminal domain and the arrangements of the dimers are completely unalike. Horseradish peroxidase (HRP) is a difficult protein to express in its native state from E. coli, and refolding from inclusion bodies is required. As a result of its varied and widespread commercial use, there is interest in the production of a recyclable form of HRP. Finally, we have demonstrated that the efficiency, stability, and homogeneity of our self-assembly system allows the direct comparison of enzyme kinetic parameters for the soluble and fibrillar forms of the same protein construct, which provides insight into the effects of immobilization and thus strategies for further optimization and development. Thus, the prion domain of Ure2 appears to be an ideal scaffold for the immobilization and display of active enzymes on amyloid fibrils as well as a new vehicle to understand fibril assembly.
Experimental Section
Materials
Unless otherwise stated, reagents were purchased from Sigma (Sigma–Aldrich co. LLC), and solutions were made using water purified to a resistance of 18.2 MΩ (Millipore). Protein concentrations were determined by absorbance at 280 nm using extinction coefficients of 48 220 (WT Ure2), 33 140 (AP constructs), or 13 050 m−1 cm−1 (HRP constructs; the prion domain of Ure2 contains no Tyr, Trp, or Cys residues), or by bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc.) following the addition of 2 % SDS and incubation at RT for at least 1 h to dissolve fibrils.
Protein expression and purification
Standard molecular cloning techniques were used to fuse together genes that encode the prion domain of Ure2 and AP (the E. coli K-12 gene was kindly provided by Prof. Qun Wei, Beijing Normal University, China) or HRP (synthetic HRP isoenzyme C (HRP-C)21). WT Ure2 and Ure21−93-AP were cloned into a mini-pRSETa expression vector (kindly provided by Dr. Mark Bycroft, MRC LMB) and expressed with an N-terminal 6x-His tag. WT HRP and all HRP chimeras were cloned into pET24a expression vectors for expression without His tags.
WT Ure2, WT AP and Ure21−93-AP were expressed in C41 E. coli in 2×YT media. The cells were grown at 37 °C to an optical density 600 nm of 0.6, induced with 0.4 mm isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown at 16 °C for 20 h. The cells were harvested by centrifugation at 5000×g for 50 min and resuspended in buffer A (50 mm Tris-HCl, 150 mm NaCl, pH 8.0). Cells were then lysed by using a high-pressure cell press (JNBIO JN-3000 PLUS), and the insoluble material was removed by centrifugation at 30 000×g for 60 min. The soluble Ure2 and Ure21−93-AP contained in the supernatants were applied to nickel-affinity chromatography resin (Chelating Sepharose Fast Flow, Amersham Biosciences) and purified according to manufacturer’s guidelines. Imidazole was removed from the purified proteins by buffer exchange into buffer A by using Amicon centrifugal concentrators (Millipore). Soluble WT AP was further purified by anion-exchange chromatography by using a Q Sepharose Fast Flow column (Amersham Biosciences). The purity of the proteins was estimated by SDS-PAGE to be >95 %.
WT HRP, Ure21−93-HRP and Ure21−80-HRP were expressed in BL21 E. coli at 16 °C in 2×YT media after induction with 0.2 mm IPTG. The cells were harvested by centrifugation at 5000×g for 50 min and resuspended in 50 mm Tris-HCl, 10 mm ethylenediaminetetraacetic acid (EDTA), and 1 mm 1,4-dithiothreitol (DTT), pH 8.0 buffer. Following pressure lysis, WT HRP, Ure21−93-HRP, and Ure21−80-HRP were purified and refolded from inclusion bodies using a modified version of the method described previously.21 In brief, the purified WT HRP, Ure21−93-HRP, and Ure21−80-HRP inclusion bodies were dissolved in 8 m Urea, 50 mm Tris-HCl, and 1 mm DTT, pH 8.0. The denatured proteins were refolded by stepwise dilution in 2 m urea that contained 50 mm Tris-HCl (pH 8.0), 8 mm CaCl2, and 0.7 mm glutathione disulfide (GSSG). First, the inclusion body mixture (100 mL) was added to an equal volume of refolding buffer, and heme was added to a final concentration of 10 μm. After 30 min, further folding buffer/inclusion body mixture (200 mL) was added into the original, and the heme concentration was adjusted back to 10 μm by further addition of stock solution. This was repeated until the final volume of the mixture reached 1 L over a period of approximately 17 h at 4 °C to a final protein concentration of 0.2 mg mL−1. Heme precipitate was removed by centrifugation, and the protein was concentrated by using an Amicon centrifugal concentrator (Millipore) to a final volume of 90–100 mL. The refolded WT HRP, Ure21−93-HRP, and Ure21−80-HRP were then dialyzed against buffer B (20 mm Na acetate, pH 4.3, that contained 1 mm CaCl2). Again, the purity of the proteins estimated by SDS-PAGE was >95 %. A UV/Vis spectrum of the protein preparations showed a five-coordinate high-spin spectrum typical of active peroxidase with Reinheitszahl (RZ; a measure of the hemin content by the absorbance ratio A403/A275) values of >2.7.
Fibril formation
Ure21−93-AP fibrils were formed by incubation at 4 °C for 2 days without shaking. WT Ure2, Ure21−93-HRP, and Ure21−80-HRP fibrils were formed by shaking at 220 rpm (Refrigerated Incubator Shaker, Innova 4230, New Brunswick Scientific) at 30 °C. The protein concentrations used for fibril formation were typically 50–70 μm. Fibril formation was monitored by ThT fluorescence as described previously22 and/or the resulting fibrils were characterized by negative-staining TEM. Conditions were chosen to allow the reproducible formation of fibrils of consistent lengths and diameters and without the loss of enzyme activity or the formation of amorphous aggregates.
Electron microscopy
For negative-staining TEM, 6 μL drops of suspensions of fibrils or soluble proteins (protein concentration around 30 μm) were loaded onto glow-discharged carbon-coated grids for 1 min and blotted with filter paper to remove extra sample, then rinsed with deionized water (6 μL) and stained with 2 % uranyl acetate for 20 s. Micrographs were recorded by using a CM120-FEG (FEI) microscope operating at 100 kV.
CD spectroscopy
CD spectra were obtained by using a Pistar-180 instrument at RT. All spectra were measured using a 1 mm pathlength quartz cuvette, 1 nm step size, and 2 nm slit width in buffer A for Ure21−93-AP and buffer B for Ure21−80-HRP, using protein concentrations of 6 and 3 μm, respectively.
X-ray fiber diffraction
Chimeric fibrils were washed with deionized water three times to remove salts, then the washed fibrils were dried and aligned on the end of a glass capillary, as described previously.23 X-ray diffraction patterns of the dehydrated fibril stalks were collected by using a Rigaku R-AXIS IV++ image-plate system calibrated against high-density polyethylene (HDPE). The sample–detector distance was 250 mm and the exposure time was 30 s. The 2 D diffraction patterns were converted into tiff images by using fit-2D and integrated into 1 D scattering profiles by using Image J.23
Western blot
Protein fibrils were washed with buffer three times, resuspended in buffer at concentrations of 40–70 μm, and incubated with 0.5 mg mL−1 proteinase K (Amresco) and 1 mm CaCl2 for more than 24 h at 37 °C. Insoluble material was collected by centrifugation at 10 000×g for 15 min at 4 °C, washed twice with buffer, dissolved in 8 m urea, and boiled in the presence of 2 % SDS for SDS-PAGE. Proteins in the gels were subjected to silver staining or transferred to polyvinylidene difluoride (PVDF) membrane for Western blot. A polyclonal anti-Ure2 antibody (made by Sino Biological Inc., China) was used to test the immunospecificity of the samples.
Cross-seeding assay
To generate seeds, fibrils were diluted to 2–3 μm and sonicated (750 Watt Ultrasonic Processors, SONICS) at 30 % power for 1 min (1 s on and 1 s off) in Eppendorf tubes incubated on ice. The fibril seeds diluted with buffer A were used to seed the fibril formation of Ure2 and Ure21−93-AP, and seeds diluted with buffer B were used to seed Ure21−93-HRP and Ure21−80-HRP fibril formation. Solutions of Ure2 and chimeric proteins (30–40 μm) contained 2–3 % seeds of Ure2 or Ure21−93-AP, or 4 % seeds of Ure21−93-HRP or Ure21−80-HRP. For the Ure2-AP cross-seeding assays, Ure2 or Ure21–93-AP (150 μL; soluble protein or seeds) was loaded into 96-well plates and shaken at 30 °C. Fibril formation was monitored by ThT fluorescence (17 μm ThT) by using a plate-reader (SpectraMax M3 Multi-Mode Microplate Reader, Molecular Devices). For Ure21−93-HRP and Ure21−80-HRP, the seeding mixture was divided into 400 μL aliquots and incubated at 30 °C with 220 rpm shaking (Refrigerated Incubator Shaker, Innova 4230, New Brunswick Scientific). Fibril formation was monitored by negative-staining TEM (Ure21−93-HRP and Ure21−80-HRP fibrils do not exhibit ThT fluorescence, possibly because of quenching by the heme group of HRP).
Enzyme activity assay and recycling of fibrils
Chimeric fibrils were washed twice with buffer and recovered by centrifugation. Ure21−93-AP fibrils (600 μL, ∼30 μm) were allowed to react with pNPP (20 μL, 500 mm) for 10 min before recovery by centrifugation at 10 000×g for 10 min. The recovered fibrils were then washed with buffer A four times to ensure the complete removal of product, before beginning a new round of reaction with pNPP. The recycling was performed four times, and the mass and activity of the fibrils were measured at each round.
After reaction with ABTS, the Ure21−80-HRP fibrils became purple and could not be washed back to their original color. These product-bound fibrils showed a significant loss of activity. Therefore, 3,3′,5,5′-tetramethylbenzidine (TMB), which did not show irreversible binding to fibrils, was used instead as the substrate. Ure21−80-HRP fibrils (500 μL, ∼25 μm) were reacted with TMB (10 μL) for 10 min and recycled by centrifugation. The recycled Ure21−80-HRP fibrils were then washed with buffer B once to remove products and reacted with TMB again. The recycling was performed four times. The Ure21−80-HRP fibril mass and activity were monitored by BCA assay and ABTS, respectively, at each round of recycling.
To measure the steady-state kinetic parameters, WT AP was diluted to 0.005 μm and soluble and fibrillar Ure21−93-AP were diluted to 0.05 μm and reacted with pNPP (New England BioLabs) in the range of 3.125–1000 μm. Dynamic light scattering measurements confirmed that fibrillar Ure21−93-AP remained aggregated after dilution to 0.05 μm and incubation for 4 h. Product formation was monitored by absorbance at 405 nm for 10 min. For reactions with HRP-containing constructs, the ABTS was in the range 31.25–1500 μm. The protein concentrations used were as follows: WT HRP, soluble Ure21−80-HRP, and soluble Ure21−93-HRP 0.03 μm; fibrillar Ure21−80-HRP and fibrillar Ure21−93-HRP 0.06 μm. The peroxide concentration in all HRP assays was 2 mm. Product formation was monitored by absorbance at 405 nm for 5 min, and the initial rates of reaction were determined. The final specific activity of WT HRP was very similar to that reported previously.15
Microcolumn assay
The microcolumn device was constructed using soft lithography techniques.20, 24 The device was fabricated in polydimethylsiloxane (PDMS; Dow Corning) using SU8 on silicon masters and plasma-bonded on a glass slide to seal the device. The size of the column was 5 mm × 1 mm × 0.02 mm to give a calculated volume of less than 0.1 μL. One end of the column was blocked with 1 % agarose introduced as a solution at 100 °C into half of the device and left to cool in situ to form a gel; the other end was left open. The Ure21−93-AP and Ure21−80-HRP fibrils were washed with buffer and diluted to around 15 μm, then the fibrils were injected and trapped into the column from the open side. The interface of the blocking agarose and stacking of the enzymatic fibrils were observed by light microscopy. ThT (20 μm) was pumped into the column for approximately 10 min, then excess ThT was washed out by pumping buffer through the column. The fluorescence of the trapped fibrils was monitored by fluorescence microscopy before and after loading with ThT. After first washing with buffer A, the colorless substrate pNPP (500 μm) was introduced into the Ure21−93-AP microcolumn with a syringe pump, and the yellow product was collected from the outlet. After running pNPP, the Ure21−93-AP microcolumn was washed with buffer A to remove any substrate or product. The fluorescent substrate 2′-(2-benzothiazoyl)-6′-hydroxybenzothiazole phosphate (BBTP, AttoPhos AP fluorescent Substrate System, Promega), was then pumped into the washed Ure21−93-AP microcolumn, and the bright yellow product was collected. No cross reaction was detected between pNPP (or its product) and BBTP. The Ure21−80-HRP microcolumn was first washed with buffer B and then the substrate 10-acetyl-3,7-dihydroxyphenoxazine (ADHP, QuantaRed Enhanced Chemifluorescent HRP Substrate, Thermo) was pumped in, and the bright pink product was collected.
Blue/white selection assay
The gene fragment Ure21−93-HRP fused with BamH I sites at the two termini (B-UH-B) was amplified by polymerase chain reaction (PCR). The pUC19 plasmid (ThermoScientific) contains an ampicillin resistance gene and the lacZ gene, which encodes β-galactosidase, and contains a BamH I site. The plasmid pHSG299 (Takara) is similar to pUC19 except that it has kanamycin resistance. The B-UH-B gene and pUC19 and pHSG299 plasmids were cut with BamH I for 3 h at 30 °C and extracted from agarose gel. The linear pUC19 was treated with SAP (1000 units/mL, used at 1 μL enzyme per 10 μL of plasmid) or Ure21−93-AP fibrils (around 50 μm, 1 μL fibrils per 10 μL of plasmid) for 1 h at 37 °C. Samples that contained SAP were incubated at 70 °C for 30 min to inactivate the SAP; samples that had been treated with Ure21−93-AP fibrils instead of SAP were not subjected to this treatment, but the Ure21−93-AP fibrils were removed by centrifugation at 12 000×g for 10 min and recycled. The recycled Ure21−93-AP fibrils were washed twice with deionized water and used to treat the linear pUC19 and pHSG299 plasmids for 1 h at 37 °C, then the plasmids were separated from Ure21−93-AP fibrils by centrifugation at 12 000×g for 10 min. All SAP- and Ure21−93-AP fibril-treated plasmids were ligated to the B-UH-B gene (also cut with BamH I) by T4 ligase for 12 h at 16 °C. As controls, linear pUC19 and pHSG299 were treated with buffer instead of SAP or Ure21−93-AP before ligation with the gene fragments. All ligation products were transformed into Top10 cells and spread on 2×YT plates coated with IPTG and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal). After approximately 14 h incubation at 37 °C, the plates were photographed and the blue (negative) colonies and white (positive) colonies were counted by using Image J software.
Acknowledgments
Work in the Perrett laboratory is supported by the 973 Program [2006CB500703, 2006CB910903] and the NSFC [31110103914, 31070656, 31100564]. E.B.S. was supported by a CAS Fellowship for Young International Scientists [2101Y2SB01] and NSFC Research Funds for Young International Scientists [31150110150 and 31350110221]. A.P.J is supported by a CAS Fellowship for Senior International Scientists [2010T1S11]. We thank Prof. Qun Wei (BNU) and Dr. Mark Bycroft (MRC LMB) for the provision of plasmids. We thank Yanxia Jia and Yongsheng Chen (Center for Biological Imaging, IBP, CAS) for assistance with TEM experiments.
Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/cctc.201402125.
References
- [1a].Kelly JW. Curr. Opin. Struct. Biol. 1996;6:11–17. doi: 10.1016/s0959-440x(96)80089-3. [DOI] [PubMed] [Google Scholar]
- [1b].Sunde M, Blake C. Adv. Protein Chem. 1997;50 doi: 10.1016/s0065-3233(08)60320-4. [DOI] [PubMed] [Google Scholar]
- [1c].Kelly JW. Curr. Opin. Struct. Biol. 1998;8 doi: 10.1016/s0959-440x(98)80016-x. [DOI] [PubMed] [Google Scholar]
- [2a].Olsén A, Jonsson A, Normark S. Nature. 1989;338:652–655. doi: 10.1038/338652a0. [DOI] [PubMed] [Google Scholar]
- [2b].Wickner RB. Science. 1994;264 doi: 10.1126/science.7909170. [DOI] [PubMed] [Google Scholar]
- [3a].Makin OS, Serpell LC. FEBS J. 2005;272:5950–5961. doi: 10.1111/j.1742-4658.2005.05025.x. [DOI] [PubMed] [Google Scholar]
- [3b].Forman CJ, Nickson AA, Anthony-Cahill SJ, Baldwin AJ, Kaggwa G, Feber U, Sheikh K, Jarvis SP, Barker PD. ACS Nano. 2012;6 doi: 10.1021/nn204140a. [DOI] [PubMed] [Google Scholar]
- [4a].Gazit E. Chem. Soc. Rev. 2007;36:1263–1269. doi: 10.1039/b605536m. [DOI] [PubMed] [Google Scholar]
- [4b].Pilkington SM, Roberts SJ, Meade SJ, Gerrard JA. Biotechnol. Prog. 2010;26 doi: 10.1002/btpr.309. [DOI] [PubMed] [Google Scholar]
- [5a].Scheibel T, Parthasarathy R, Sawicki G, Lin XM, Jaeger H, Lindquist SL. Proc. Natl. Acad. Sci. USA. 2003;100:4527–4532. doi: 10.1073/pnas.0431081100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5b].Baldwin AJ, Bader R, Christodoulou J, MacPhee CE, Dobson CM, Barker PD. J. Am. Chem. Soc. 2006;128 doi: 10.1021/ja0565673. [DOI] [PubMed] [Google Scholar]
- [6a].Men D, Guo YC, Zhang ZP, Wei HP, Zhou YF, Cui ZQ, Liang XS, Li K, Leng Y, You XY, Zhang XE. Nano Lett. 2009;9:2246–2250. doi: 10.1021/nl9003464. [DOI] [PubMed] [Google Scholar]
- [6b].Leng Y, Wei HP, Zhang ZP, Zhou YF, Deng JY, Cui ZQ, Men D, You XY, Yu ZN, Luo M, Zhang XE. Angew. Chem. Int. Ed. 2010;49 doi: 10.1002/anie.201002452. [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2010;122 [Google Scholar]
- [7a].Masison DC, Wickner RB. Science. 1995;270:93–95. doi: 10.1126/science.270.5233.93. [DOI] [PubMed] [Google Scholar]
- [7b].Taylor KL, Cheng NQ, Williams RW, Steven AC, Wickner RB. Science. 1999;283 doi: 10.1126/science.283.5406.1339. [DOI] [PubMed] [Google Scholar]
- [8a].Baxa U, Speransky V, Steven AC, Wickner RB. Proc. Natl. Acad. Sci. USA. 2002;99:5253–5260. doi: 10.1073/pnas.082097899. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8b].Baxa U, Taylor KL, Wall JS, Simon MN, Cheng NQ, Wickner RB, Steven AC. J. Biol. Chem. 2003;278 doi: 10.1074/jbc.M306004200. [DOI] [PubMed] [Google Scholar]
- [8c].Kryndushkin DS, Wickner RB, Tycko R. J. Mol. Biol. 2011;409 doi: 10.1016/j.jmb.2011.03.067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8d].Wang YQ, Bongiovanni M, Gras SL, Perrett S. J. Struct. Biol. 2011;174 doi: 10.1016/j.jsb.2011.03.008. [DOI] [PubMed] [Google Scholar]
- [8e].Habenstein B, Bousset L, Sourigues Y, Kabani M, Loquet A, Meier BH, Melki R, Bockmann A. Angew. Chem. Int. Ed. 2012;51 doi: 10.1002/anie.201202093. [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2012;124 [Google Scholar]
- [9a].Coschigano PW, Magasanik B. Mol. Cell. Biol. 1991;11:822–832. doi: 10.1128/mcb.11.2.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9b].Bousset L, Belrhali H, Janin J, Melki R, Morera S. Structure. 2001;9 doi: 10.1016/s0969-2126(00)00553-0. [DOI] [PubMed] [Google Scholar]
- [9c].Umland TC, Taylor KL, Rhee S, Wickner RB, Davies DR. Proc. Natl. Acad. Sci. USA. 2001;98 doi: 10.1073/pnas.041607898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10a].Bai M, Zhou JM, Perrett S. J. Biol. Chem. 2004;279:50025–50030. doi: 10.1074/jbc.M406612200. [DOI] [PubMed] [Google Scholar]
- [10b].Zhang ZR, Perrett S. J. Biol. Chem. 2009;284 doi: 10.1074/jbc.M901189200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Yu Y, Wang HY, Bai M, Perrett S. Biochem. J. 2011;434:143–151. doi: 10.1042/BJ20101895. [DOI] [PubMed] [Google Scholar]
- [12].Buttstedt A, Winter R, Sackewitz M, Hause G, Schmid FX, Schwarz E. PLoS ONE. 2010;5:15436. doi: 10.1371/journal.pone.0015436. e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13a].Tischer W, Wedekind F. Top. Curr. Chem. 1999;200:95–126. [Google Scholar]
- [13b].Sheldon RA. Adv. Synth. Catal. 2007;349 [Google Scholar]
- [14a].Jia HF, Zhu GY, Vugrinovich B, Kataphinan W, Reneker DH, Wang P. Biotechnol. Prog. 2002;18:1027–1032. doi: 10.1021/bp020042m. [DOI] [PubMed] [Google Scholar]
- [14b].Jia HF, Zhu GY, Wang P. Biotechnol. Bioeng. 2003;84 doi: 10.1002/bit.10781. [DOI] [PubMed] [Google Scholar]
- [14c].Fan J, Lei J, Wang LM, Yu CZ, Tu B, Zhao DY. Chem. Commun. 2003 doi: 10.1039/b304391f. [DOI] [PubMed] [Google Scholar]
- [14d].Kim J, Grate JW, Wang P. Chem. Eng. Sci. 2006;61 [Google Scholar]
- [14e].Wang ZG, Wan LS, Liu ZM, Huang XJ, Xu ZK. J. Mol. Catal. B. 2009;56 [Google Scholar]
- [15].Smith AT, Sanders SA, Thorneley RN, Burke JF, Bray RR. Eur. J. Biochem. 1992;207:507–519. doi: 10.1111/j.1432-1033.1992.tb17077.x. [DOI] [PubMed] [Google Scholar]
- [16].Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CCF. J. Mol. Biol. 1997;273:729–739. doi: 10.1006/jmbi.1997.1348. [DOI] [PubMed] [Google Scholar]
- [17].Baxa U, Cheng N, Winkler DC, Chiu TK, Davies DR, Sharma D, Inouye H, Kirschner DA, Wickner RB, Steven AC. J. Struct. Biol. 2005;150:170–179. doi: 10.1016/j.jsb.2005.02.007. [DOI] [PubMed] [Google Scholar]
- [18].Veitch NC, Smith AT. Adv. Inorg. Chem. 2000;51:107–162. [Google Scholar]
- [19].Berglund GI, Carlsson GH, Smith AT, Szoke H, Henriksen A, Hajdu J. Nature. 2002;417:463–468. doi: 10.1038/417463a. [DOI] [PubMed] [Google Scholar]
- [20].Qin D, Xia YN, Whitesides GM. Nat. Protoc. 2010;5:491–502. doi: 10.1038/nprot.2009.234. [DOI] [PubMed] [Google Scholar]
- [21].Smith AT, Santama N, Dacey S, Edwards M, Bray RC, Thorneley RNF, Burke JF. J. Biol. Chem. 1990;265:13335. [PubMed] [Google Scholar]
- [22].Zhu L, Zhang X-J, Wang L-Y, Zhou J-M, Perrett S. J. Mol. Biol. 2003;328:235. doi: 10.1016/s0022-2836(03)00249-3. [DOI] [PubMed] [Google Scholar]
- [23].Gras SL, Squires AM. Protein Folding, Misfolding, and Disease: Methods and Protocols. 2011;752:147. [Google Scholar]
- [24].Mazutis L, Gilbert J, Ung WL, Weitz DA, Griffiths AD, Heyman JA. Nat. Protoc. 2013;8:870. doi: 10.1038/nprot.2013.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.